Dr Tilly Bingham

Tilly Bingham is a drug discoverer with over 18 years’ experience of working in the pharmaceutical R&D sector in ‘large pharma’ (Organon, Schering-Plough, MSD), Biotech (Redx Pharma) and is currently VP of Science at Concept Life Sciences. Tilly’s early career was spent working as a medicinal chemist in CNS therapeutic areas where her research focussed on design strategies for getting small molecule therapeutics across the blood brain barrier. More recently as Head of Research and Operations at Redx Pharma she oversaw the discovery and development of oncology and fibrosis clinical and pre-clinical candidates, including the clinical candidate porcupine inhibitors RXC004 (oncology), RXC006 (fibrosis) and BTK inhibitor LOXO-305. She is currently VP of Science at Concept Life Sciences overseeing multiple programmes in Hit-to-Lead and Lead Optimisation. Tilly is an elected member of the Organic Division of the Royal Society of Chemistry and a member of the SCI fine chemicals group and has authored over 40 papers, patents and publications including the RSC book “Drug Discovery for Psychiatric Disorders”